These findings highlight the therapeutic potential of targeting the TGF-β/Smad pathway and enhancing FBLN1 expression to alleviate ARDS-associated oxidative stress and ferroptosis. The gene discussed is TGFB1; the disease is acute respiratory distress syndrome.